Related Experiment Video

Updated: Nov 2, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.9K

Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis

Lin Xia1, Tiantian Shen1, Wenliang Dong2

  • 1Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China; Department of Pharmacy, Peking University People's Hospital, Beijing, China.

Diabetes Research and Clinical Practice
|June 8, 2021
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively lower blood glucose and promote weight loss in type 2 diabetes (T2D). However, most GLP-1RAs showed similar safety profiles, suggesting personalized treatment approaches.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes (T2D) management requires effective therapies for glycemic control and weight reduction.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of drugs used in T2D treatment.
  • Comparative effectiveness data for various GLP-1RAs is crucial for clinical decision-making.

Purpose of the Study:

  • To compare and rank the efficacy of 8 GLP-1RAs in lowering blood glucose and promoting weight loss in patients with T2D.
  • To evaluate the safety profiles, including adverse event withdrawals and hypoglycemia incidence, of these GLP-1RAs.
  • To provide evidence for individualized GLP-1RA selection based on patient characteristics.

Main Methods:

  • A systematic literature search was conducted in PubMed, EMBASE, and CENTRAL up to April 13, 2021.
  • Network meta-analysis was employed to estimate standardized mean differences for glycemic control (Δ HbA1c) and weight loss (Δ weight).
  • Summary odds ratios were calculated for adverse event withdrawals and hypoglycemia incidence.

Main Results:

  • All evaluated GLP-1RAs, except for albiglutide-30 mg QW, demonstrated superior efficacy over placebo in improving glycemic control and/or promoting weight loss.
  • Oral semaglutide-14 mg QD, semaglutide-1 mg QW, liraglutide-1.8 mg QD, and exenatide-2 ug BID were associated with a higher risk of adverse event withdrawals.
  • Hypoglycemia incidence was higher with most GLP-1RAs compared to placebo, with exceptions including albiglutide-30 mg QW and orally administered semaglutide-14 mg QD.

Conclusions:

  • GLP-1RAs are generally effective in improving glycemic control and facilitating weight loss in patients with T2D.
  • Significant differences in safety profiles among GLP-1RAs were largely not observed.
  • Individualized GLP-1RA administration, considering blood glucose levels and obesity, is a potential strategy for optimizing T2D management.
Keywords:
A network meta-analysisEfficacyGLP-1RAsSafetyType 2 diabetes

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.4K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

751

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
507
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
341
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
314
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
378
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
345
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
452